Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.

NCT01168791 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT01168791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01168791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.
Lead sponsor
Alaunos Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
August 16, 2010
Completion date
March 13, 2013
Enrollment
447 (actual)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma